Cardior Pharmaceuticals GmbH

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
microRNA-132RNA / oligonucleotide
Heart Failure

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
May 2027 (1)
CDR132LPhase 2Heart Failure
Est. primary completion 2027-05-16 · NCT06979375 · CT.gov ↗
What to watch
November 2027 (1)
CDR132LPhase 2Heart Failure
Est. primary completion 2027-11-16 · NCT06979362 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

10 May 2026Topline resultCDR132LHF-REVERT (NCT05350969) presented at Heart Failure 2026: primary endpoint (LVESVI) not met

Financial reports

No financial reports recorded.